Replies to post #130957 on Biotech Values

[DewDiligence]

…companies cannot deny [Ponatinib] to patients who are resistant/intolerant to Gleevec - that would be tantamount to killing them. So even under more restrictive reimbursement settings, the fight would be over 1st line for high-risk patients, not 2nd or 3rd-line.

You conveniently ignore that there are other second-line agents for patients who are resistant/intolerant to Gleevec.

The Sprycel patent runs until 2020. It's a novel compound, no re-patenting issues. Filings by generic companies are a dime a dozen. If BMY was truly concerned about the patent they would settle and knock a few years off the date. In the big scheme of things I don't even view this filing as a rounding error in figuring ARIA's valuation.

This is a lame response, IMO. BMY just found out about the P-IV challenge a few days ago.